RCKT ROCKET PHARMACEUTICALS, INC.

BEARISH Impact: 7/10 S-3
Horizon weeks Filed Mar 2, 2026 Processed 3mo ago SEC 0001140361-26-007341
Shelf registration — potential dilution
Final — all horizons settled through T+60d
RCKT ▼ -37.71% at T+60d
SHORT call ✓ call won +37.71% · α vs SPY +48.03% · entry $4.80 → $2.99
Last close $2.70 (close Jun 8) · +43.75% from $4.80 entry (call sign-flipped)
Entry anchored
Mar 2, 03:59 PM ET
via Databento tick
T+1d
+0.42%
call -0.42% · α +0.34%
$4.82
settled 3mo ago
T+5d
+10.42%
call -10.42% · α -10.89%
$5.30
settled 3mo ago
T+20d
-25.42%
call +25.42% · α +21.01%
$3.58
settled 2mo ago
T+60d
-37.71%
call +37.71% · α +48.03%
$2.99
settled 14d ago

Price Chart

Loading chart...

Executive Summary

Rocket Pharmaceuticals has filed a shelf registration (S-3) for up to $400 million in securities, including common stock, preferred stock, debt, warrants, or units. This filing signals potential future dilutive capital raises but does not specify immediate issuance. The company is a small-cap biotech with a market cap of $3 million, recently restructuring to extend its cash runway.

Key Financial Metrics

Offering Size
$400.0M

Actionable Insight

Monitor for future prospectus supplements that will disclose specific offering terms. The massive size of this shelf relative to market cap suggests potential for significant dilution. Watch for insider selling patterns and upcoming clinical trial data that could trigger an offering.

Key Facts

  • Rocket Pharmaceuticals filed an S-3 shelf registration for up to $400,000,000 in securities (common stock, preferred stock, debt, warrants, or units)
  • Market cap is only $3 million, meaning the offering could represent over 13,000% of current market value if fully utilized
  • No specific offering details provided - this is a registration for potential future issuances
  • Company recently implemented a 30% workforce reduction and cut operating expenses by 25% to extend cash runway
  • Company is focused on late-stage gene therapy development for rare diseases with high unmet medical need

Financial Impact

Up to $400 million in potential dilutive capital raises, representing over 13,000% of current $3 million market cap

dilutionmarket capshare countequity value

Risk Factors

  • Extreme dilution risk given shelf size is 13,000%+ of current market cap
  • Biotech clinical trial failure risk for gene therapy programs
  • Potential for opportunistic offering at inflated prices if near-term catalysts boost share price

Market Snapshot

Exchange
Nasdaq

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001140361-26-007341
Document: ny20066752x1_ex4-4.htm0001140361-26-007341
CONTEXT: 10-Q (2025-11-06)0001193125-25-269474
4 reports for RCKT
Performance horizon
Filters
Rows
Reports for RCKT — sortable, filterable
Type Now
May 26, 2026
14d ago
Insider Cluster
NEUTRAL ★ 3/10
$2.99 $2.92▼ −2.34%▼ −2.81%$2.70 (−9.70%)
May 7, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.25 $2.96▼ −8.92%▼ −9.89%$2.70 (−16.92%)
Mar 11, 2026
13w ago
EFFECT
NEUTRAL ★ 4/10
$4.96 $4.47▼ −9.88%▼ −7.69%$2.70 (−45.56%)
Mar 2, 2026
14w ago
S-3
BEARISH ★ 7/10
$4.80 $5.30▼ −10.42%▼ −10.89%$2.70 (+43.75%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 6h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access